Using the BLRR system, we monitored altered DSB repair dynamics induced by small-molecule modulators, and subsequently revealed that anti-tumour cardiac glycosides inhibit HDR function in human glioblastomas (GBMs) and patient-derived GBM cancer stem cells (GSCs) via suppression of RAD51 recombinase. The gene discussed is RAD51; the disease is glioblastoma.